HINT1 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered from the HAP1 human cell line, featuring targeted disruption of the HINT1 gene. This product comprises a heterogeneous pool of cells carrying loss-of-function mutations at the HINT1 locus, providing a versatile platform for investigating the tumor-suppressive and metabolic functions of HINT1. The polyclonal format reflects a population-level knockout model, suitable for pooled functional screens and comparative analyses against wild-type HAP1 controls. Researchers can employ these cells to dissect HINT1-dependent pathways in a near-haploid genetic background without the bias of clonal selection.
HAP1 is a near-haploid human chronic myeloid leukemia (CML) cell line derived from the KBM-7 parental line. Its haploid karyotype simplifies genetic manipulation and facilitates high-quality sequencing, genotyping, and copy-number variation analyses. HAP1 cells are widely adopted for CRISPR-based screens, drug sensitivity profiling, and mechanistic studies in cancer biology. The cell line retains key signaling pathways relevant to leukemia and apoptosis, making it a robust host for interrogating tumor suppressor genes. In this context, HINT1 knockout in HAP1 cells permits direct assessment of gene function in a disease-relevant, hematologic malignancy model.
HINT1 encodes a nucleotide phosphoramidase and acyl-AMP hydrolase that operates at the intersection of purine metabolism, apoptosis, and transcription. Functioning as a tumor suppressor, HINT1 hydrolyzes nucleotide substrates and modulates cell-fate decisions through physical interactions with multiple partners. Notably, HINT1 binds the microphthalmia-associated transcription factor (MITF), repressing its transcriptional activity and thereby influencing downstream gene expression programs. Additionally, HINT1 interacts with protein kinase C (PKC) isozymes, linking metabolic signals to proliferative and apoptotic cascades. The protein is transcriptionally regulated by p53 upon DNA damage and feeds into the activation of caspases, the executioners of apoptosis. This network positions HINT1 as a critical rheostat for cellular stress responses, connecting purine metabolism to tumor suppression and transcriptional control.
In the HAP1 background, HINT1 disruption eliminates its tumor-suppressive constraints, allowing investigation into unchecked MITF activity, altered PKC signaling, and resistance to apoptosis. The polyclonal population recapitulates knockout heterogeneity, enabling robust detection of functional consequences without clonal artifacts. Because HAP1 cells maintain an intact p53 pathway, the model is ideal for studying DNA damage-induced apoptosis and p53-dependent transcriptional programs. Moreover, the haploid nature of HAP1 reduces functional redundancy, sharpening the phenotypic readouts of HINT1 loss. This combination makes the polyclonal HINT1 knockout HAP1 cells particularly valuable for unbiased genetic screens and dose-response assays in a leukemic cellular environment.
Researchers can employ these cells in a wide range of assays: western blotting confirms HINT1 protein loss; RT-qPCR monitors changes in MITF target genes and apoptosis regulators; apoptosis assays quantify caspase activation and viability; cell viability assays evaluate clonogenic growth; and reporter gene assays directly measure MITF-driven transcription. Co-immunoprecipitation studies elucidate HINT1 interactome dynamics in the knockout context. Applications span cancer research, neurodegenerative disease modeling, and drug target discovery, especially in pathways intersecting purine salvage and tumor suppression. The polyclonal HINT1 knockout HAP1 cells serve as a cost-effective, genetically defined tool for high-throughput functional genomics and preclinical evaluation. For additional product information or custom cell engineering requests, please contact Ascent Research.
